Skip to main content
AHG logo

AHG · Akso Health Group

Track AHG — free
$0.86 -0.12 (-12.57%) At close · Aug 28
Market Cap
$734.02M
Shares
856.70M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.86 Open$0.91 Day$0.85–0.95 52W close$0.86–2.50 Avg vol 30d15K Short int19K · 0.0% float · 1.9d Short vol12% DataAug 2020–Aug 2026

Raw chart and full-history price indicators begin at the captured split on Aug 24, 2020; bars on opposite sides are not compared.

Up next

FQ2-27 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −47%
below
Price vs 50-day avg −37%
below
RSI (14) 29
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −45%
trailing
6-month return −37%
trailing
YTD return −48%
this year
Relative strength −50%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+83% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -18.4% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
11 holders — near 3-yr high, broad support
Squeeze score 26
low risk · 0–100
Fundamentals
Weak
Revenue growth −6%
Y/Y
Gross margin -0%
expanding
EPS growth −94%
Y/Y
Free cash flow $-12.8M
Buyback $25.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 88%
annualized · 1-yr
Max drawdown −66%
past year
ATR 14.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−47% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
29 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+83% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -18.4% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
11 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $3
vs 200-day avg -47% vs 50-day avg -37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Distribution — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AHG
Akso Health Group
this stock
$734.02M -47.8% -6.4% 0.0%
MCK
Mckesson Corp
$103.82B +8.9% +3.1% 23.9 2.1%
COR
Cencora, Inc.
$61.58B -4.7% +9.3% 24.0 2.4%
CAH
Cardinal Health Inc
$54.55B +14.1% +14.2% 2.7%
HSIC
Henry Schein Inc
$10.06B +18.4% +5.9% 26.3 6.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
11
% held
0.0%
Net QoQ
+54.7K sh
Top holder
RENAISSANCE TECHNOLOGIES…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
18.9K
Days to cover
1.9d
Change
-4.3K sh
View
Short Volume
Short vol %
12%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
13
Value
$19
As of
Jul 24, 2026
View
Off-Exchange
Off-exchange %
42.0%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$13.8M
Net income (FY)
$-18.7M
EPS diluted
$0.01
View
Buybacks
Authorized
$25.0M
View
Filings
SEC Filings
Latest
20-F
Filed
Jul 23, 2026
This year
4
View

Performance

Raw-price comparisons begin at the captured split on Aug 24, 2020; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
AHG -7.9% -45.4% -36.5% -45.4% -47.8%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -8.3% -48.4% -50.0% -48.4% -60.6%

Capital returns

Buyback program · as of Dec 10, 2018
Authorized
$25.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1702318 CUSIP 98422P108 13F (30d) 11 filings 11 filers Visit website